CN102989009B - 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法 - Google Patents
预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法 Download PDFInfo
- Publication number
- CN102989009B CN102989009B CN201210472073.1A CN201210472073A CN102989009B CN 102989009 B CN102989009 B CN 102989009B CN 201210472073 A CN201210472073 A CN 201210472073A CN 102989009 B CN102989009 B CN 102989009B
- Authority
- CN
- China
- Prior art keywords
- gene
- cell
- seq
- expression
- expressed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010061535 Ovarian neoplasm Diseases 0.000 title claims abstract description 118
- 206010033128 Ovarian cancer Diseases 0.000 title claims abstract description 114
- 238000000034 method Methods 0.000 title abstract description 187
- 238000002512 chemotherapy Methods 0.000 title abstract description 52
- 206010009944 Colon cancer Diseases 0.000 title description 34
- 208000029742 colonic neoplasm Diseases 0.000 title description 30
- 210000004027 cell Anatomy 0.000 claims abstract description 318
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 71
- 238000011282 treatment Methods 0.000 claims abstract description 30
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 116
- 229960004316 cisplatin Drugs 0.000 claims description 116
- 239000003112 inhibitor Substances 0.000 claims description 61
- 108020004459 Small interfering RNA Proteins 0.000 claims description 48
- 102000003900 Calpain-2 Human genes 0.000 claims description 47
- 108090000232 Calpain-2 Proteins 0.000 claims description 47
- 239000003814 drug Substances 0.000 claims description 41
- 238000002360 preparation method Methods 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 126
- 150000001875 compounds Chemical class 0.000 abstract description 76
- 239000002246 antineoplastic agent Substances 0.000 abstract description 26
- 206010059866 Drug resistance Diseases 0.000 abstract description 20
- 229940044683 chemotherapy drug Drugs 0.000 abstract description 19
- 238000012544 monitoring process Methods 0.000 abstract description 16
- 230000004565 tumor cell growth Effects 0.000 abstract description 8
- 230000000973 chemotherapeutic effect Effects 0.000 abstract description 7
- 238000012216 screening Methods 0.000 abstract description 4
- 239000003966 growth inhibitor Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 512
- 230000014509 gene expression Effects 0.000 description 202
- 102000004169 proteins and genes Human genes 0.000 description 93
- 108020004999 messenger RNA Proteins 0.000 description 77
- 239000011575 calcium Substances 0.000 description 67
- 239000000523 sample Substances 0.000 description 67
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 66
- 229910052791 calcium Inorganic materials 0.000 description 66
- -1 Fused toes Proteins 0.000 description 65
- 238000000636 Northern blotting Methods 0.000 description 59
- 230000000694 effects Effects 0.000 description 55
- 102100029811 Protein S100-A11 Human genes 0.000 description 51
- 102100029796 Protein S100-A10 Human genes 0.000 description 48
- 201000011510 cancer Diseases 0.000 description 48
- 238000010586 diagram Methods 0.000 description 42
- 102000039446 nucleic acids Human genes 0.000 description 42
- 108020004707 nucleic acids Proteins 0.000 description 42
- 150000007523 nucleic acids Chemical class 0.000 description 42
- 238000004458 analytical method Methods 0.000 description 39
- 230000002441 reversible effect Effects 0.000 description 38
- 102100039725 AH receptor-interacting protein Human genes 0.000 description 35
- 108010054017 Granulocyte Colony-Stimulating Factor Receptors Proteins 0.000 description 35
- 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 description 35
- 102100023479 Vinexin Human genes 0.000 description 35
- 101710187710 Vinexin Proteins 0.000 description 35
- 230000008569 process Effects 0.000 description 35
- 101000959526 Homo sapiens AH receptor-interacting protein Proteins 0.000 description 33
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 33
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 33
- 102100037118 Scavenger receptor class B member 1 Human genes 0.000 description 33
- 101150088682 HMT-1 gene Proteins 0.000 description 32
- 101100490834 Homo sapiens ALG1 gene Proteins 0.000 description 32
- 101000605522 Homo sapiens Kallikrein-1 Proteins 0.000 description 32
- 101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 description 32
- 101100216116 Homo sapiens PRMT2 gene Proteins 0.000 description 32
- 101000782180 Homo sapiens WD repeat-containing protein 1 Proteins 0.000 description 32
- 102100034866 Kallikrein-6 Human genes 0.000 description 32
- 102100022988 Protein arginine N-methyltransferase 2 Human genes 0.000 description 32
- 102100036551 WD repeat-containing protein 1 Human genes 0.000 description 32
- 102100021676 Baculoviral IAP repeat-containing protein 1 Human genes 0.000 description 31
- 102000002639 Eukaryotic Initiation Factor-2B Human genes 0.000 description 31
- 108010082945 Eukaryotic Initiation Factor-2B Proteins 0.000 description 31
- 108010006696 Neuronal Apoptosis-Inhibitory Protein Proteins 0.000 description 31
- 108091005487 SCARB1 Proteins 0.000 description 31
- 230000003750 conditioning effect Effects 0.000 description 31
- 102100027674 CTD small phosphatase-like protein Human genes 0.000 description 30
- 102100038712 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 1 Human genes 0.000 description 30
- 101000725950 Homo sapiens CTD small phosphatase-like protein Proteins 0.000 description 30
- 101000883304 Homo sapiens Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 1 Proteins 0.000 description 30
- 101001130686 Homo sapiens Ras-related protein Rab-22A Proteins 0.000 description 30
- 101150018665 MAPK3 gene Proteins 0.000 description 30
- 102100031782 Metallothionein-1L Human genes 0.000 description 30
- 101710196487 Metallothionein-1L Proteins 0.000 description 30
- 102100031516 Ras-related protein Rab-22A Human genes 0.000 description 30
- 229960000936 fumagillin Drugs 0.000 description 30
- NGGMYCMLYOUNGM-UHFFFAOYSA-N (-)-fumagillin Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)C=CC=CC=CC=CC(O)=O)CCC21CO2 NGGMYCMLYOUNGM-UHFFFAOYSA-N 0.000 description 29
- 102100029228 Insulin-like growth factor-binding protein 7 Human genes 0.000 description 29
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 29
- 108090000192 Methionyl aminopeptidases Proteins 0.000 description 29
- 102100030569 Nuclear receptor corepressor 2 Human genes 0.000 description 29
- 102100023609 Nucleoside diphosphate kinase, mitochondrial Human genes 0.000 description 29
- NGGMYCMLYOUNGM-CSDLUJIJSA-N fumagillin Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)C[C@@]21CO2 NGGMYCMLYOUNGM-CSDLUJIJSA-N 0.000 description 29
- 108010008598 insulin-like growth factor binding protein-related protein 1 Proteins 0.000 description 29
- 210000003371 toe Anatomy 0.000 description 29
- 108050008354 Heat shock factor protein 2 Proteins 0.000 description 28
- 102100034049 Heat shock factor protein 2 Human genes 0.000 description 28
- 101100404397 Homo sapiens NME4 gene Proteins 0.000 description 28
- 101000582254 Homo sapiens Nuclear receptor corepressor 2 Proteins 0.000 description 28
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 28
- 239000008194 pharmaceutical composition Substances 0.000 description 28
- 229910052725 zinc Inorganic materials 0.000 description 28
- 239000011701 zinc Substances 0.000 description 28
- 101000865408 Homo sapiens Double-stranded RNA-specific adenosine deaminase Proteins 0.000 description 27
- 102100029791 Double-stranded RNA-specific adenosine deaminase Human genes 0.000 description 26
- 102100036498 Dual specificity testis-specific protein kinase 2 Human genes 0.000 description 26
- 101710117201 Fas-activated serine/threonine kinase Proteins 0.000 description 26
- 102100029531 Fas-activated serine/threonine kinase Human genes 0.000 description 26
- 101000714156 Homo sapiens Dual specificity testis-specific protein kinase 2 Proteins 0.000 description 26
- 101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 description 26
- 102100037001 Next to BRCA1 gene 1 protein Human genes 0.000 description 26
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 26
- 102100039776 39S ribosomal protein L4, mitochondrial Human genes 0.000 description 25
- 101000667416 Homo sapiens 39S ribosomal protein L4, mitochondrial Proteins 0.000 description 25
- 201000010099 disease Diseases 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 25
- 238000012360 testing method Methods 0.000 description 24
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 23
- 239000000047 product Substances 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 21
- 238000001514 detection method Methods 0.000 description 20
- 230000008859 change Effects 0.000 description 19
- 239000002299 complementary DNA Substances 0.000 description 19
- 230000035945 sensitivity Effects 0.000 description 19
- 239000002773 nucleotide Substances 0.000 description 18
- 125000003729 nucleotide group Chemical group 0.000 description 18
- 230000006870 function Effects 0.000 description 17
- 230000001225 therapeutic effect Effects 0.000 description 17
- 230000002829 reductive effect Effects 0.000 description 16
- 238000011160 research Methods 0.000 description 15
- 230000004083 survival effect Effects 0.000 description 15
- 230000012010 growth Effects 0.000 description 14
- 238000011534 incubation Methods 0.000 description 14
- 238000012797 qualification Methods 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- 230000002611 ovarian Effects 0.000 description 13
- 229910052697 platinum Inorganic materials 0.000 description 13
- 230000004614 tumor growth Effects 0.000 description 13
- 230000008878 coupling Effects 0.000 description 12
- 238000010168 coupling process Methods 0.000 description 12
- 238000005859 coupling reaction Methods 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 230000009368 gene silencing by RNA Effects 0.000 description 11
- 238000001890 transfection Methods 0.000 description 11
- 108091030071 RNAI Proteins 0.000 description 10
- 230000010261 cell growth Effects 0.000 description 10
- 230000002759 chromosomal effect Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000013604 expression vector Substances 0.000 description 10
- 230000001629 suppression Effects 0.000 description 10
- 108700026244 Open Reading Frames Proteins 0.000 description 9
- 230000000630 rising effect Effects 0.000 description 9
- 239000004055 small Interfering RNA Substances 0.000 description 9
- 230000008685 targeting Effects 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 102000007590 Calpain Human genes 0.000 description 8
- 108010032088 Calpain Proteins 0.000 description 8
- 239000002131 composite material Substances 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 238000011529 RT qPCR Methods 0.000 description 7
- 210000000349 chromosome Anatomy 0.000 description 7
- 229940127089 cytotoxic agent Drugs 0.000 description 7
- 238000002651 drug therapy Methods 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 210000001672 ovary Anatomy 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 102100025418 Zinc finger MYM-type protein 4 Human genes 0.000 description 6
- 239000012190 activator Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 238000011321 prophylaxis Methods 0.000 description 6
- 238000005245 sintering Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 241001597008 Nomeidae Species 0.000 description 5
- MSHZHSPISPJWHW-UHFFFAOYSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)NC(=O)CCl)CCC21CO2 MSHZHSPISPJWHW-UHFFFAOYSA-N 0.000 description 5
- 108091081021 Sense strand Proteins 0.000 description 5
- 108091027967 Small hairpin RNA Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 230000008707 rearrangement Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000005026 transcription initiation Effects 0.000 description 5
- 230000005030 transcription termination Effects 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 101150084557 EIF5 gene Proteins 0.000 description 4
- 241000206602 Eukaryota Species 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000030944 contact inhibition Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 239000005090 green fluorescent protein Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000004481 post-translational protein modification Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108010038798 Actin Depolymerizing Factors Proteins 0.000 description 3
- 102000015693 Actin Depolymerizing Factors Human genes 0.000 description 3
- 241000710929 Alphavirus Species 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 101000741929 Caenorhabditis elegans Serine/threonine-protein phosphatase 2A catalytic subunit Proteins 0.000 description 3
- 101000909256 Caldicellulosiruptor bescii (strain ATCC BAA-1888 / DSM 6725 / Z-1320) DNA polymerase I Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- RJWLAIMXRBDUMH-ULQDDVLXSA-N N-Acetylleucyl-leucyl-methioninal Chemical compound CSCC[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(C)=O RJWLAIMXRBDUMH-ULQDDVLXSA-N 0.000 description 3
- 125000003047 N-acetyl group Chemical group 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 208000037062 Polyps Diseases 0.000 description 3
- 101000902592 Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1) DNA polymerase Proteins 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- 241001365914 Taira Species 0.000 description 3
- 101710161999 Zinc finger MYM-type protein 4 Proteins 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000004953 colonic tissue Anatomy 0.000 description 3
- 201000010989 colorectal carcinoma Diseases 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 238000010208 microarray analysis Methods 0.000 description 3
- 230000010355 oscillation Effects 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 241001225321 Aspergillus fumigatus Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 2
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 102000002241 Eukaryotic Initiation Factors Human genes 0.000 description 2
- 108010014863 Eukaryotic Initiation Factors Proteins 0.000 description 2
- 101000740659 Homo sapiens Scavenger receptor class B member 1 Proteins 0.000 description 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102100037514 Metallothionein-1F Human genes 0.000 description 2
- 101710196495 Metallothionein-1F Proteins 0.000 description 2
- 101710181812 Methionine aminopeptidase Proteins 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108700025695 Suppressor Genes Proteins 0.000 description 2
- 239000012163 TRI reagent Substances 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 108010091545 acetylleucyl-leucyl-norleucinal Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 108010021842 aryl hydrocarbon receptor-interacting protein Proteins 0.000 description 2
- 229940091771 aspergillus fumigatus Drugs 0.000 description 2
- 230000003305 autocrine Effects 0.000 description 2
- XKUTVNLXHINPAP-UHFFFAOYSA-N azane platinum Chemical compound N.[Pt] XKUTVNLXHINPAP-UHFFFAOYSA-N 0.000 description 2
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 108010053420 calpain inhibitor 2 Proteins 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000006114 decarboxylation reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 102000005525 fibrillarin Human genes 0.000 description 2
- 108020002231 fibrillarin Proteins 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940074869 marquis Drugs 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 210000003632 microfilament Anatomy 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000010413 mother solution Substances 0.000 description 2
- 239000002088 nanocapsule Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 230000003076 paracrine Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000001855 preneoplastic effect Effects 0.000 description 2
- 201000001514 prostate carcinoma Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- TYIRBZOAKBEYEJ-UHFFFAOYSA-N 2-(1,3-dimethyl-2,6-dioxopurin-7-yl)ethyl 2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetate Chemical compound C1=CC(C)=CC=C1C(=O)C(N1C)=CC=C1CC(=O)OCCN1C(C(=O)N(C)C(=O)N2C)=C2N=C1 TYIRBZOAKBEYEJ-UHFFFAOYSA-N 0.000 description 1
- 102100039217 3-ketoacyl-CoA thiolase, peroxisomal Human genes 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 102100036664 Adenosine deaminase Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108700040618 BRCA1 Genes Proteins 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 206010004433 Benign ovarian tumour Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- 229940121926 Calpain inhibitor Drugs 0.000 description 1
- 102100035037 Calpastatin Human genes 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 102000003668 Destrin Human genes 0.000 description 1
- 108090000082 Destrin Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 108030004793 Dual-specificity kinases Proteins 0.000 description 1
- 102100020987 Eukaryotic translation initiation factor 5 Human genes 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108090001064 Gelsolin Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102100022083 Grancalcin Human genes 0.000 description 1
- 101710124985 Grancalcin Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 1
- 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 101100153048 Homo sapiens ACAA1 gene Proteins 0.000 description 1
- 101001002481 Homo sapiens Eukaryotic translation initiation factor 5 Proteins 0.000 description 1
- 101000577080 Homo sapiens Mitochondrial-processing peptidase subunit alpha Proteins 0.000 description 1
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 1
- 101001112313 Homo sapiens Nucleoside diphosphate kinase, mitochondrial Proteins 0.000 description 1
- 101000757216 Homo sapiens Protein arginine N-methyltransferase 1 Proteins 0.000 description 1
- 101000873927 Homo sapiens Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 description 1
- 101000590687 Homo sapiens U3 small nucleolar ribonucleoprotein protein MPP10 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 101150090079 MPP10 gene Proteins 0.000 description 1
- 101150024075 Mapk1 gene Proteins 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 102100028379 Methionine aminopeptidase 1 Human genes 0.000 description 1
- 101710161855 Methionine aminopeptidase 1 Proteins 0.000 description 1
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 1
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 1
- 101150115413 NBR1 gene Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 description 1
- MSHZHSPISPJWHW-PVDLLORBSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)NC(=O)CCl)C[C@@]21CO2 MSHZHSPISPJWHW-PVDLLORBSA-N 0.000 description 1
- 108010077077 Osteonectin Proteins 0.000 description 1
- 102000009890 Osteonectin Human genes 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100022985 Protein arginine N-methyltransferase 1 Human genes 0.000 description 1
- 101710204571 Protein phosphatase PP2A regulatory subunit A Proteins 0.000 description 1
- 102000017143 RNA Polymerase I Human genes 0.000 description 1
- 108010013845 RNA Polymerase I Proteins 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 108050002651 Retinoblastoma-like protein 2 Proteins 0.000 description 1
- 101150036757 SPARC gene Proteins 0.000 description 1
- 238000010818 SYBR green PCR Master Mix Methods 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 108020004688 Small Nuclear RNA Proteins 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 102100026834 Sorbin and SH3 domain-containing protein 1 Human genes 0.000 description 1
- 102100026901 Sorbin and SH3 domain-containing protein 2 Human genes 0.000 description 1
- 101710089386 Sorbin and SH3 domain-containing protein 2 Proteins 0.000 description 1
- 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 description 1
- GFKPPJZEOXIRFX-UHFFFAOYSA-N TCA A Natural products CC(CCC(=O)O)C1=CCC2(C)OC3=C(CC12)C(=O)C(O)CC3 GFKPPJZEOXIRFX-UHFFFAOYSA-N 0.000 description 1
- 102100032497 U3 small nucleolar ribonucleoprotein protein MPP10 Human genes 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 108091034131 VA RNA Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- FMYKJLXRRQTBOR-BZSNNMDCSA-N acetylleucyl-leucyl-norleucinal Chemical compound CCCC[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(C)=O FMYKJLXRRQTBOR-BZSNNMDCSA-N 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 101150036080 at gene Proteins 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- 108010079785 calpain inhibitors Proteins 0.000 description 1
- 108010044208 calpastatin Proteins 0.000 description 1
- 108010086826 calponin Proteins 0.000 description 1
- 102000006783 calponin Human genes 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 238000011500 cytoreductive surgery Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- UKNNCBXEELDDCU-SUJAAXHWSA-N fumagalone Chemical compound O=C[C@@]1(O)CCC(=O)[C@@H](OC)[C@@H]1[C@]1(C)[C@@H](CC=C(C)C)O1 UKNNCBXEELDDCU-SUJAAXHWSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- NESRXFGQJARQNM-OWYFMNJBSA-N graphinone Chemical compound O=C([C@H]([C@]1(O)[C@]2(C)[C@H](O2)CC=C(C)C)OC)CC[C@@]21CO2 NESRXFGQJARQNM-OWYFMNJBSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000025278 malignant myoepithelioma Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 101150026150 mt gene Proteins 0.000 description 1
- 201000008405 myoepithelial carcinoma Diseases 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000019581 neuron apoptotic process Effects 0.000 description 1
- 230000009223 neuronal apoptosis Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008016 ovarian benign neoplasm Diseases 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000012660 pharmacological inhibitor Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 108010055499 ponsin Proteins 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 102000004217 thyroid hormone receptors Human genes 0.000 description 1
- 108090000721 thyroid hormone receptors Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000004572 zinc-binding Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53350503P | 2003-12-31 | 2003-12-31 | |
| US60/533,505 | 2003-12-31 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2004800421486A Division CN1922332B (zh) | 2003-12-31 | 2004-12-30 | 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102989009A CN102989009A (zh) | 2013-03-27 |
| CN102989009B true CN102989009B (zh) | 2015-06-03 |
Family
ID=34748910
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2004800421486A Expired - Fee Related CN1922332B (zh) | 2003-12-31 | 2004-12-30 | 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法 |
| CN201110195193.7A Expired - Fee Related CN102321584B (zh) | 2003-12-31 | 2004-12-30 | 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法 |
| CN201210472073.1A Expired - Fee Related CN102989009B (zh) | 2003-12-31 | 2004-12-30 | 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2004800421486A Expired - Fee Related CN1922332B (zh) | 2003-12-31 | 2004-12-30 | 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法 |
| CN201110195193.7A Expired - Fee Related CN102321584B (zh) | 2003-12-31 | 2004-12-30 | 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US7700280B2 (enExample) |
| EP (2) | EP2395112B1 (enExample) |
| JP (3) | JP4682152B2 (enExample) |
| CN (3) | CN1922332B (enExample) |
| ES (1) | ES2394799T3 (enExample) |
| TW (1) | TWI301066B (enExample) |
| WO (1) | WO2005066371A2 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4682152B2 (ja) * | 2003-12-31 | 2011-05-11 | ザ・ペン・ステート・リサーチ・ファンデーション | 卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法 |
| AU2006249235B2 (en) * | 2004-05-14 | 2010-11-11 | Abraxis Bioscience, Llc | Sparc and methods of use thereof |
| US8420603B2 (en) * | 2004-05-14 | 2013-04-16 | Abraxis Bioscience, Llc | SPARC and methods of use thereof |
| EP3327031A1 (en) * | 2004-05-14 | 2018-05-30 | Abraxis BioScience, LLC | Disease site-delivering pharmaceutical compositions comprising paclitaxel |
| US7553496B2 (en) * | 2004-12-21 | 2009-06-30 | University Of Kentucky Research Foundation | VEGF-A as an inhibitor of angiogenesis and methods of using same |
| US8445198B2 (en) | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| WO2007072225A2 (en) * | 2005-12-01 | 2007-06-28 | Medical Prognosis Institute | Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| ES2432759T3 (es) * | 2006-06-13 | 2013-12-05 | The Rockefeller University | Nuevos métodos de diagnóstico |
| DE102006035393A1 (de) * | 2006-11-02 | 2008-05-15 | Signature Diagnostics Ag | Prognostische Marker für die Klassifizierung des dreijährigen progessionsfreien Überlebens von Patienten mit Kolonkarzinomen basierend auf Expressionsprofilen von biologischen Proben |
| US20110178154A1 (en) * | 2007-02-06 | 2011-07-21 | Birrer Michael J | gene expression profile that predicts ovarian cancer subject response to chemotherapy |
| WO2008109519A2 (en) * | 2007-03-02 | 2008-09-12 | University Of South Florida | Micro-rna profiles associated with endometrial cancer development and response to cisplatin and doxorubicin chemotherapy |
| KR20100065189A (ko) | 2007-09-11 | 2010-06-15 | 유니버시티 오브 매사추세츠 | 암을 치료하기 위한 인슐린유사 성장 인자 결합 단백질 7 |
| BRPI0906573A2 (pt) * | 2008-01-31 | 2015-07-07 | Univ Keio | Método para determinação da sensibilidade para agentes anticâncer |
| US8093000B2 (en) * | 2008-05-09 | 2012-01-10 | The Regents Of The University Of California | Methods for predicting and treating tumors resistant to drug, immunotherapy, and radiation |
| WO2010135786A1 (en) * | 2009-05-29 | 2010-12-02 | Clinical Genomics Pty. Ltd. | A method for diagnosing neoplasms and molecules for use therein |
| CA2767621A1 (en) * | 2009-07-09 | 2011-01-13 | Abraxis Bioscience, Llc | Sparc antisense compositions and uses thereof |
| DK177532B1 (en) | 2009-09-17 | 2013-09-08 | Bio Bedst Aps | Medical use of sPLA2 hydrolysable liposomes |
| US20120245089A1 (en) * | 2009-09-18 | 2012-09-27 | Abraxis Bioscience, Llc | Use of the sparc microenvironment signature in the treatment of cancer |
| EP3081941B1 (en) * | 2009-10-30 | 2018-06-27 | Keio University | Method for determination of sensitivity to anti-cancer agent |
| WO2011135459A2 (en) | 2010-04-29 | 2011-11-03 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy |
| EP3858385B1 (en) | 2010-05-25 | 2024-09-11 | Syndevrx, Inc. | Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof |
| MX2012013874A (es) | 2010-06-03 | 2013-01-24 | Abraxis Bioscience Llc | Uso de la signatura en el microentorno de sparc en el tratamiento de cancer. |
| WO2012110425A1 (en) * | 2011-02-14 | 2012-08-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for monitoring the response to treatment and for treating colorectal cancer |
| EA201691257A1 (ru) | 2011-06-02 | 2017-02-28 | Олмак Дайэгностикс Лимитед | Молекулярно-диагностический тест на рак |
| US9409978B2 (en) * | 2011-09-09 | 2016-08-09 | University Of Massachusetts | Modulation of midbody derivatives |
| HK1214633A1 (zh) | 2012-12-03 | 2016-07-29 | Almac Diagnostics Limited | 癌症的分子诊断测试 |
| MX371095B (es) | 2013-04-10 | 2020-01-16 | Syndevrx Inc | Inhibidores de metionina aminopeptidasa-2 y metodos de tratamiento de la obesidad. |
| GB201409479D0 (en) | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
| CN103893763B (zh) * | 2014-04-10 | 2016-05-11 | 武汉大学 | Vinexin-β基因在心肌梗死中的应用 |
| CA2955914C (en) * | 2014-07-21 | 2022-09-06 | Ignacio Canals Almazan | Tungsten (vi) salts for use thereof in the treatment of infertility, for favoring normal reproduction and fertility in a non-diabetic female mammal, as well as for improving the efficacy of assisted reproductive techniques |
| US10570457B2 (en) | 2014-09-26 | 2020-02-25 | Medical Prognosis Institute A/S | Methods for predicting drug responsiveness |
| CN108290853B (zh) | 2015-12-10 | 2022-05-31 | 辛德弗雷克斯公司 | 烟曲霉醇衍生物及其多晶型物 |
| CA3008960C (en) | 2016-01-11 | 2024-07-02 | Syndevrx, Inc. | TREATMENT OF TUMORS INDUCED BY METABOLIC DYSFUNCTION |
| US9725769B1 (en) | 2016-10-07 | 2017-08-08 | Oncology Venture ApS | Methods for predicting drug responsiveness in cancer patients |
| AU2017258901A1 (en) | 2016-12-30 | 2018-07-19 | Allarity Therapeutics Europe ApS | Methods for predicting drug responsiveness in cancer patients |
| EP3714896A4 (en) * | 2017-11-21 | 2021-08-04 | Miwa, Naofumi | HUMAN CANCER CELL METASTASIS INHIBITOR AND HUMAN CANCER CELL DETERMINATION AGENT |
| CN113196055B (zh) | 2018-10-15 | 2025-06-27 | 马克斯·普朗克科学促进协会 | 用于治疗疾病的化合物及其筛选方法 |
| EP3870231A1 (en) | 2018-10-26 | 2021-09-01 | Syndevrx, Inc. | Biomarkers of metap2 inhibitors and applications thereof |
| WO2020163795A1 (en) | 2019-02-08 | 2020-08-13 | Dewpoint Therapeutics, Inc. | Methods of characterizing condensate-associated characteristics of compounds and uses thereof |
| AU2020274530A1 (en) * | 2019-05-15 | 2021-12-16 | Whitehead Institute For Biomedical Research | Methods of characterizing and utilizing agent-condensate interactions |
| CN110331203B (zh) * | 2019-07-30 | 2023-04-18 | 中南大学湘雅三医院 | 泛素连接酶chaf1b作为靶位点在制备肺腺癌顺铂增敏药物中的应用 |
| CN114729941A (zh) | 2019-09-18 | 2022-07-08 | 露点治疗公司 | 筛选凝聚物相关特异性的方法及其用途 |
| EP4329778A4 (en) * | 2021-04-26 | 2025-02-19 | Crititech, Inc. | CISPLATIN PARTICLES AND THEIR USES |
| US20250304625A1 (en) * | 2022-04-06 | 2025-10-02 | Vanderbilt University | Articles and methods for inhibiting methionine aminopeptidase activity |
| WO2025057928A1 (ja) * | 2023-09-11 | 2025-03-20 | 国立大学法人大阪大学 | 細胞外小胞内ｒｎａ修飾による卵巣癌プラチナ製剤抵抗性を判別するための検査方法 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0642589A4 (en) | 1992-05-11 | 1997-05-21 | Ribozyme Pharm Inc | METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION. |
| CA2140343A1 (en) | 1992-07-17 | 1994-02-03 | Sean M. Sullivan | Method and reagent for treatment of animal diseases |
| US5624803A (en) | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
| US5902880A (en) | 1994-08-19 | 1999-05-11 | Ribozyme Pharmaceuticals, Inc. | RNA polymerase III-based expression of therapeutic RNAs |
| US7625697B2 (en) * | 1994-06-17 | 2009-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for constructing subarrays and subarrays made thereby |
| US6146886A (en) | 1994-08-19 | 2000-11-14 | Ribozyme Pharmaceuticals, Inc. | RNA polymerase III-based expression of therapeutic RNAs |
| CA2207593A1 (en) | 1994-12-13 | 1996-06-20 | John Gustofson | Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses |
| US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| JP2001510808A (ja) | 1997-07-24 | 2001-08-07 | イネックス ファーマシューティカルズ コーポレイション | 核酸触媒の供給のためのリポソーム組成物 |
| AR013269A1 (es) | 1997-08-04 | 2000-12-13 | Scras | Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral |
| WO1999031262A2 (en) | 1997-12-16 | 1999-06-24 | Valentis, Inc. | Needle-free injection of formulated nucleic acid molecules |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US6680175B2 (en) * | 1998-05-05 | 2004-01-20 | Adherex Technologies, Inc. | Methods for diagnosing and evaluating cancer |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| EP2314700A1 (en) | 1999-01-28 | 2011-04-27 | Medical College of Georgia Research Institute, Inc | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| ATE408699T1 (de) | 1999-03-10 | 2008-10-15 | Phogen Ltd | Verabreichung von nukleinsäuren und proteinen an zellen |
| AU7058000A (en) * | 1999-08-13 | 2001-03-13 | Human Genome Sciences, Inc. | 13 human colon and colon cancer associated proteins |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| US20020051978A1 (en) * | 2000-02-17 | 2002-05-02 | Roth Frederick P. | Methods and compositions for the identification, assessment, prevention and therapy of human cancers |
| AU2001253140A1 (en) * | 2000-04-03 | 2001-10-15 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Tumor markers in ovarian cancer |
| CA2418320A1 (en) * | 2000-08-11 | 2002-02-21 | City Of Hope | The anti-neoplastic agent et-743 inhibits trans activation by sxr |
| EP1330652B1 (en) * | 2000-10-27 | 2007-06-27 | Mount Sinai Hospital | Method for detecting ovarian cancer based on human kallikrein 6 (hk6) |
| US20020182619A1 (en) * | 2000-11-08 | 2002-12-05 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer |
| US7195868B2 (en) * | 2001-04-18 | 2007-03-27 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the identification, assessment, prevention, and therapy of human cancers |
| AU2000280389A1 (en) | 2001-11-02 | 2003-05-19 | Dana-Farber Cancer Institute | Methods and compositions for the diagnosis of cancer susceptibilities and defective dna repair mechanisms and treatment thereof |
| WO2003045323A2 (en) * | 2001-11-28 | 2003-06-05 | Mediomics, Llc | Anti-angiogenesis methods, compositions and uses therefor |
| AU2003225851A1 (en) * | 2002-03-15 | 2003-09-29 | The Texas A&M University System | Strong gene sets for glioma classification |
| US20040097452A1 (en) * | 2002-11-19 | 2004-05-20 | Isis Pharmaceuticals Inc. | Modulation of kallikrein 6 expression |
| JP4682152B2 (ja) * | 2003-12-31 | 2011-05-11 | ザ・ペン・ステート・リサーチ・ファンデーション | 卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法 |
| WO2006044017A2 (en) * | 2004-08-13 | 2006-04-27 | Jaguar Bioscience Inc. | Systems and methods for identifying diagnostic indicators |
-
2004
- 2004-12-30 JP JP2006547537A patent/JP4682152B2/ja not_active Expired - Fee Related
- 2004-12-30 CN CN2004800421486A patent/CN1922332B/zh not_active Expired - Fee Related
- 2004-12-30 WO PCT/US2004/043837 patent/WO2005066371A2/en not_active Ceased
- 2004-12-30 ES ES04815833T patent/ES2394799T3/es not_active Expired - Lifetime
- 2004-12-30 US US11/026,734 patent/US7700280B2/en not_active Expired - Lifetime
- 2004-12-30 EP EP11163049.7A patent/EP2395112B1/en not_active Expired - Lifetime
- 2004-12-30 CN CN201110195193.7A patent/CN102321584B/zh not_active Expired - Fee Related
- 2004-12-30 EP EP04815833A patent/EP1704250B1/en not_active Expired - Lifetime
- 2004-12-30 CN CN201210472073.1A patent/CN102989009B/zh not_active Expired - Fee Related
- 2004-12-31 TW TW093141829A patent/TWI301066B/zh not_active IP Right Cessation
-
2010
- 2010-02-23 US US12/711,056 patent/US20100221730A1/en not_active Abandoned
- 2010-02-23 US US12/711,036 patent/US20100221729A1/en not_active Abandoned
- 2010-02-23 US US12/711,068 patent/US8192935B2/en not_active Expired - Fee Related
- 2010-03-31 JP JP2010081265A patent/JP5285012B2/ja not_active Expired - Fee Related
-
2012
- 2012-12-12 JP JP2012271426A patent/JP5789591B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-24 US US15/052,422 patent/US20160348180A1/en not_active Abandoned
Non-Patent Citations (2)
| Title |
|---|
| Analysis of molecular profile data using generative and discriminative methods;E.J.Moler et al.;《Physiological Genomics》;20000101;第4卷;全文 * |
| siRNA-mediated antitumorigenesis for drug target validation and therapeutics;Lu PY et al.;《Europe PubMed Central》;20030630;第5卷(第3期);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005066371A3 (en) | 2006-04-20 |
| US20100221731A1 (en) | 2010-09-02 |
| US20100221730A1 (en) | 2010-09-02 |
| US20160348180A1 (en) | 2016-12-01 |
| US20050176669A1 (en) | 2005-08-11 |
| JP2007517058A (ja) | 2007-06-28 |
| US7700280B2 (en) | 2010-04-20 |
| CN102321584A (zh) | 2012-01-18 |
| CN102989009A (zh) | 2013-03-27 |
| US8192935B2 (en) | 2012-06-05 |
| US20100221729A1 (en) | 2010-09-02 |
| JP5789591B2 (ja) | 2015-10-07 |
| JP5285012B2 (ja) | 2013-09-11 |
| JP4682152B2 (ja) | 2011-05-11 |
| JP2013079261A (ja) | 2013-05-02 |
| EP1704250B1 (en) | 2012-09-19 |
| WO2005066371A2 (en) | 2005-07-21 |
| EP1704250A2 (en) | 2006-09-27 |
| JP2010209076A (ja) | 2010-09-24 |
| ES2394799T3 (es) | 2013-02-05 |
| CN1922332B (zh) | 2013-06-12 |
| TWI301066B (en) | 2008-09-21 |
| CN1922332A (zh) | 2007-02-28 |
| EP2395112B1 (en) | 2017-02-15 |
| EP2395112A1 (en) | 2011-12-14 |
| CN102321584B (zh) | 2014-01-08 |
| TW200531682A (en) | 2005-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102989009B (zh) | 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法 | |
| US9062351B2 (en) | Diagnostic, prognostic and therapeutic uses of long non-coding RNAs for cancer and regenerative medicine | |
| Iiizumi et al. | EphA4 receptor, overexpressed in pancreatic ductal adenocarcinoma, promotes cancer cell growth | |
| WO2005089735A2 (en) | Compositions and methods for treating lung cancer | |
| WO2016141375A1 (en) | Her2-regulated rna as diagnostic and therapeutic targets in her2-positive breast cancer | |
| CN107164554B (zh) | Asprv1作为生物标志物在喉鳞癌诊疗中的应用 | |
| CN110452989B (zh) | 生物标志物在胃癌检测、诊断中的应用 | |
| Lu et al. | Downregulation of long non-coding RNA LINP1 inhibits the malignant progression of esophageal squamous cell carcinoma | |
| CN108707672A (zh) | Duxap8在肝细胞癌诊断和治疗中的应用 | |
| US8486905B2 (en) | Use of FLJ25416 gene | |
| CN108384858B (zh) | 肺癌相关基因及其在肺癌诊治中的应用 | |
| CN114908100B (zh) | 人HHIPL1 mRNA在食管鳞状细胞癌靶向治疗和预后评估中的应用及试剂盒 | |
| CN119082310B (zh) | Aml诊断和预后预测相关的生物标志物及其应用 | |
| KR101808658B1 (ko) | 암 진단 키트 및 암 예방 또는 치료용 약제학적 조성물 | |
| CN108165624A (zh) | 生物标志物在骨肉瘤诊治中的应用 | |
| KR101466661B1 (ko) | Ｔｍｃ５ 유전자의 신규한 용도 | |
| KR101115443B1 (ko) | 대장암 진단용 조성물 및 그 용도 | |
| CN114854856A (zh) | Arpc1b基因的相关用途及药物 | |
| CN116904591A (zh) | 一种甲状腺乳头状癌的LncRNA标志物及其应用 | |
| CN107988374A (zh) | 一种与骨肉瘤相关的分子标志物及其应用 | |
| KR20100065898A (ko) | Ｌｏｃ２８４４２２ 유전자의 신규한 용도 | |
| WO2007116923A2 (en) | Sez6l2 oncogene as a therapeutic target and prognostic indicator for lung cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150603 Termination date: 20201230 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |